Dupilumab pharmacokinetics and effect on type 2 biomarkers in children with moderate-to-severe asthma
Jackson, Daniel J. (University of Wisconsin School of Medicine and Public Health)
Bacharier, Leonard B. (Monroe Carell Jr Children's Hospital at Vanderbilt University Medical Center, Nashville, Tennessee)
Phipatanakul, Wanda (Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts)
Sher, Lawrence (Peninsula Research Associates, Rolling Hills Estates, California.)
Domingo, Christian (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Papadopoulos, Nikolaos (University of Athens, Greece)
Modena, Brian (Modena Allergy & Asthma, La Jolla, California)
Li, Ning (Department of Immunology, Sanofi, Beijing, People's Republic of China)
Xia, Changming (Regeneron Pharmaceuticals (Tarrytown, New York))
Kamal, Mohamed A. (Regeneron Pharmaceuticals (Tarrytown, New York))
Dillon, Myles (Regeneron Pharmaceuticals (Tarrytown, New York))
Wolfe, Kelley (Department of Immunology, Sanofi, Bridgewater, New Jersey)
Gall, Rebecca (Regeneron Pharmaceuticals (Tarrytown, New York))
Amin, Nikhil (Regeneron Pharmaceuticals (Tarrytown, New York))
Mannent, Leda P. (Department of Immunology, Sanofi, Chilly-Mazarin, France)
Laws, Elizabeth (Sanofi (Bridgewater, New Jersey))
Rowe, Paul J. (Sanofi (Bridgewater, New Jersey))
Jacob-Nara, Juby A. (Sanofi (Bridgewater, New Jersey))
Deniz, Yamo (Regeneron Pharmaceuticals (Tarrytown, New York))
Lederer, David J. (Regeneron Pharmaceuticals (Tarrytown, New York))
Hardin, Megan (Sanofi (Cambridge, Estats Units d'Amèrica))
Xu, Christine (Sanofi (Bridgewater, New Jersey))
Universitat Autònoma de Barcelona. Departament de Medicina

Date:	2023
Abstract:	Background: Type 2 inflammation is common in children with asthma. Dupilumab, a human antibody, blocks the signaling of interleukin -4 and -13, key and central drivers of type 2 inflammation. In the LIBERTY ASTHMA VOYAGE (NCT02948959) study, dupilumab reduced severe asthma exacerbations and improved lung function in children aged 6 to 11 years with uncontrolled, moderate-to-severe asthma. Objective: To assess the pharmacokinetics of dupilumab and type 2 biomarker changes in children with type 2 asthma in VOYAGE. Methods: Patients were randomized to dupilumab 100 mg (≤30 kg) or 200 mg (.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Published in:	Annals of Allergy, Asthma and Immunology, Vol. 131, Núm. 1 (july 2023) , p. 44-51.e4, ISSN 1534-4436

DOI: 10.1016/j.anai.2023.03.014

12 p, 1.9 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Parc Taulí Research and Innovation Institute (I3PT
Articles > Research articles
Articles > Published articles